Progress in preventing kidney cancer recurrence
Cancer “adjuvant” therapies are treatments designed to reduce the chances of tumors coming back after surgery. But for decades, attempts to find adjuvant treatments for kidney cancer failed to...
Cancer “adjuvant” therapies are treatments designed to reduce the chances of tumors coming back after surgery. But for decades, attempts to find adjuvant treatments for kidney cancer failed to...
Using genetic information to match patients to targeted therapies may improve survival in people with a fast-moving leukemia. Because acute myeloid leukemia is such a fast-moving and deadly cancer,...
The Beat AML clinical trial has matched 250 study participants to targeted treatments for acute myeloid leukemia – with promising early results. Regulators were wary of the complicated study...
A $10 million gift from The Harry T. Mangurian Jr. Foundation will help The Leukemia & Lymphoma Society expand the Beat AML Master Trial underway at the OHSU Knight Cancer Institute and other...
The best available treatment for acute myeloid leukemia is a drug combination established more than 30 years ago. And today less than a third of newly diagnosed AML patients survive beyond five...